Your Eyelids Have Microbiomes.
When They Go Wrong,
You Feel It Every Morning.
Blepharitis affects up to 40% of the Indian population — and most people who have it have never heard the word. Crusty lashes, burning eyes, styes that keep returning: this is the eyelid's chronic inflammatory disease. It doesn't cure, but it controls.
population affected
have Demodex collarettes
untrained in Demodex
in adults over 70
Blepharitis is chronic inflammation of the eyelid margin — among the most common eye conditions in India, estimated to affect up to 40% of the population. Symptoms: morning crusting of lashes, itching, burning, redness, sticky eyelids, and recurring styes or chalazia. Two main types: Anterior blepharitis (outer lid margin, lash follicles — caused by Staphylococcal bacteria and Demodex mites) and Posterior blepharitis (inner lid — caused by meibomian gland dysfunction, MGD). Demodex mites are microscopic parasites in lash follicles and meibomian glands — the Titan study found 58% of eye clinic patients have collarettes, the pathognomonic sign of Demodex blepharitis. Treatment: Daily lid hygiene (warm compress 5–10 min → lid scrub with baby shampoo or commercial wipes → rinse), antibiotic drops or ointment for bacterial flares (MOXGUARD, Agaaz Ophthalmics), warm compress + massage for MGD. Blepharitis is rarely cured but is effectively controlled with consistent daily routine. India-specific note: Demodex blepharitis is highly underdiagnosed in India — 70% of practitioners have no formal training in its detection.
The Eyelid Margin:
Six Millimetres of Extraordinary Complexity
The eyelid margin — the rim you see when you look closely at your eye — is only about 6mm wide, but contains an extraordinary microenvironment that supports both vision and eye protection. Understanding why blepharitis is so common and so persistent requires understanding what lives and functions at this margin.
The upper and lower lid margins are divided anatomically by the grey line (the mucocutaneous junction) into an anterior lamella and a posterior lamella. The anterior lamella contains the skin, the orbicularis muscle, and most critically, the lash follicles — each one capable of harbouring Demodex folliculorum and bacterial colonies. The posterior lamella, separated by the grey line, contains the tarsal plate and within it, a row of 25–40 meibomian glands per eyelid — modified sebaceous glands that secrete the oily outer layer of the tear film.
The meibomian glands open at the posterior lid margin and constantly release a lipid-rich secretion (meibum) onto the eye's surface. This lipid layer prevents tear evaporation and keeps the ocular surface moist. When the meibomian glands become blocked or inflamed — as in posterior blepharitis and MGD — this lipid secretion becomes abnormal, tear film instability results, and the chronic irritation cycle of posterior blepharitis begins.
The lid margin also hosts a resident microbiome: Staphylococcus epidermidis, Corynebacterium species, and Demodex mites in normal flora. When the balance of this microbiome shifts — overgrowth of S. aureus, explosive Demodex proliferation, or dysregulation from seborrhoeic dermatitis — blepharitis develops and persists.
EYELID MARGIN CROSS-SECTION — ANTERIOR vs POSTERIOR ANATOMY
The grey line divides the lid margin. Anterior: lash follicles with Demodex and bacteria. Posterior: meibomian glands producing the tear film's oil layer — blocked in posterior blepharitis. Collarettes at the lash base are the pathognomonic sign of Demodex infestation.
Anterior or Posterior?
Two Different Diseases, Same Eyelid
- Staphylococcal overgrowth (S. epidermidis, S. aureus)
- Seborrhoeic dermatitis (dandruff of the lid margin)
- Demodex folliculorum (mite colonisation of lash follicles)
- Mixed — staphylococcal + seborrhoeic most common combination
- Collarettes — waxy cylindrical deposits at lash base
- Crusting / scurf of lashes (worse on waking)
- Lash loss (madarosis) or misdirected lashes (trichiasis)
- Follicular conjunctivitis, mild keratopathy at 2 & 10 o'clock
- Lid scrubs daily (baby shampoo / commercial wipes)
- Antibiotic ointment (chloramphenicol, fusidic acid) — lid margin application
- Tea tree oil products (for confirmed Demodex)
- Topical antibiotic drops for secondary conjunctivitis
- Oral doxycycline (low-dose) for severe/persistent cases
- Staphylococcal: good control with daily hygiene
- Demodex: requires targeted treatment, slow response (6–8 wks)
- Seborrhoeic: control of scalp dandruff also helps
- Meibomian gland dysfunction (MGD) — primary cause
- Demodex brevis (inhabits meibomian glands, causes atrophy)
- Rosacea — a major associated systemic condition
- Seborrhoeic dermatitis — often co-exists
- Atopic dermatitis, psoriasis in some patients
- Blocked meibomian gland orifices (plugged, thickened meibum)
- Lid margin telangiectasia (fine blood vessels at posterior margin)
- Frothy or foamy tear meniscus
- Irregular posterior lid margin, notching
- Decreased tear break-up time (TBUT), dry eye symptoms
- Warm compress 5–10 min (melts thickened meibum)
- Lid massage (expressed blocked glands after warming)
- Omega-3 supplementation (reduces meibum viscosity)
- Topical cyclosporine or lifitegrast for DED component
- Oral doxycycline 50–100 mg/day for 4–8 weeks
- In-office procedures: meibomian gland expression, Lipiflow
- Lid scrubs help less — warm compress + massage are primary
- Often requires treating the associated DED simultaneously
- Fluorescein staining helpful to assess ocular surface
The Demodex Mite:
What's Living at Your Lash Base
Demodex folliculorum and Demodex brevis are microscopic obligate ectoparasitic mites — members of the Arachnida class — that are the most common human ectoparasites. They live exclusively on mammalian skin, primarily the face, and have no free-living stage. D. folliculorum (0.3–0.4 mm) clusters in groups of 3–8 within the eyelash hair follicle; D. brevis (0.15–0.2 mm) inhabits the meibomian glands and sebaceous glands deeper in the lid.
In normal numbers, Demodex mites are harmless commensal organisms. Pathology occurs when mite density exceeds approximately 1 mite per eyelash — the threshold associated with clinical blepharitis. Several factors drive overpopulation:
- Age — the single strongest determinant. Demodex prevalence rises from ~8% in those under 25 years to ~77% in those over 70 years. By middle age (40–60 years), over 50% of the population has significant Demodex colonisation.
- Rosacea — patients with rosacea have dramatically elevated Demodex densities on the face and lids. Demodex is now considered a contributor to rosacea pathology, not just a bystander.
- Immunosuppression — HIV, immunosuppressive medications, and transplant patients have higher Demodex loads.
- Poor lid hygiene — accumulated sebum and debris provide an ideal growth substrate for Demodex reproduction.
- Seborrhoeic skin type — oilier skin supports larger Demodex populations.
The pathognomonic sign of Demodex blepharitis is collarettes — cylindrical, translucent-to-opaque, waxy, sleeve-like deposits that wrap around the base of eyelashes. They are composed of keratin, mite excrement, eggs, and regurgitated undigested material. Collarettes are visible at the slit lamp and, in severe cases, can be seen with a torch or loupe. Their presence confirms Demodex infestation — no other type of blepharitis produces true collarettes.
"The Titan study found that 58% of US eye care clinic patients — across all presenting complaints, not only blepharitis — exhibited collarettes, confirming that Demodex blepharitis is not a rare or specialist condition but a routine finding that demands routine screening at every slit-lamp examination."
— Adapted from Trattler W, et al. "The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes." Clin Ophthalmol. 2022;16:1153–1164.The treatment for Demodex blepharitis specifically requires agents that target the mite — standard lid hygiene is insufficient. Established approaches:
- Tea tree oil (TTO) — the historically recommended treatment. 4–50% concentrations applied by the clinician to lids; 1–2% dilutions in commercial lid wipes for home use. Terpinen-4-ol (the active component) is the most effective fraction against Demodex. Complete collarette resolution typically takes 6–8 weeks of consistent use.
- Lotilaner ophthalmic solution 0.25% (Xdemvy — Tarsus Pharmaceuticals, approved FDA 2023) — a selective antiparasitic eye drop used twice daily for 6 weeks; the first FDA-approved prescription treatment specifically for Demodex blepharitis. Not yet widely available in India as of mid-2026.
- Oral ivermectin — used off-label; modest evidence for Demodex reduction but systemic side effects limit routine use.
- Hypochlorous acid eyelid cleansers — anti-biofilm and mild anti-Demodex effect; useful as maintenance after acute treatment.
Meibomian Gland Dysfunction:
The Dominant Driver of Posterior Blepharitis
Meibomian gland dysfunction (MGD) is defined as a chronic, diffuse abnormality of the meibomian glands, commonly characterised by terminal duct obstruction and/or qualitative/quantitative changes in glandular secretion — and is the most common cause of evaporative dry eye and posterior blepharitis worldwide.
The meibomian glands (25–40 per lid) are modified holocrine sebaceous glands whose acinar cells synthesise meibum — a complex lipid mixture that forms the outermost layer of the tear film. Meibum prevents tear evaporation, contributes to tear film spreading, and protects the ocular surface. When meibomian glands become obstructed — from stagnant, keratinised ductal epithelium, thickened meibum, or Demodex brevis disruption — meibum cannot flow freely, tear film lipid layer becomes deficient, and the vicious cycle of evaporative dry eye, inflammation, and further gland damage begins.
The link between Demodex and MGD is now well-established. A 2025 study (Yeu and Koetting, published in Journal of Cataract and Refractive Surgery) found that among MGD patients, 45% had Demodex blepharitis — and among those with moderate-to-severe Demodex (≥10 collarettes), 96–99% had concurrent MGD. This bidirectional relationship means that in India, where Demodex is significantly underdiagnosed, many patients treated for "dry eye" or "MGD" are not receiving Demodex-targeted treatment — and thus not addressing a primary driving factor of their condition.
also have Demodex
patients have MGD
globally (age-dependent)
key diagnostic test
India: 40% Prevalence,
Massively Undertreated Demodex
A 2023 survey-based study on Demodex blepharitis knowledge among Indian eye care practitioners (published in Dove Press / Clinical Optometry) produced sobering findings about the state of blepharitis management in India:
- Estimated blepharitis prevalence in the general Indian population: ~40% (as reported by surveyed practitioners).
- 70% of Indian optometrists had received no formal training in Demodex detection or treatment.
- Only 30% of practitioners actively intervened to diagnose and manage Demodex blepharitis — despite 66% agreeing it was a significant cause of ocular discomfort.
- Primary management focus: improving patient comfort (40%), improving meibomian gland secretion (20.8%), eliminating mites (20.8%).
Several India-specific factors compound the blepharitis problem:
- High seborrhoeic dermatitis prevalence — seborrhoeic skin is common in India's climate, and seborrhoeic blepharitis is its ocular manifestation. Both conditions share the same Malassezia yeast contribution and respond to similar treatment (anti-dandruff shampoo for scalp, lid hygiene for lid margins).
- Smoke and pollution exposure — urban air pollution and indoor cooking smoke (biomass fuel, especially in rural areas) are significant environmental irritants that destabilise the tear film and trigger MGD exacerbations.
- Contact lens wear without lid hygiene — increasingly common among India's young urban population; contact lens wear significantly increases Demodex load and Staphylococcal lid margin colonisation.
- Extensive eye makeup use — kajal/kohl application directly to the inner lid margin is extremely common and directly obstructs meibomian gland orifices, contributing to MGD in India's female population. Kajal particles have been found in meibomian glands on meibography.
INDIA-SPECIFIC BLEPHARITIS RISK FACTORS — PREVALENCE MAPPING
Kajal (kohl, surma) applied to the inner lid margin — the waterline — is a widespread practice across all age groups in India, including in children. The inner lid margin is precisely where meibomian gland orifices open. Kajal particles physically obstruct these orifices. Studies have documented kajal particles within meibomian glands on meibography, and kajal use is an independent risk factor for MGD and posterior blepharitis. Patients with recurrent MGD or posterior blepharitis should be specifically counselled to apply kajal only to the outer lid skin, never inside the waterline.
The Lid Hygiene Routine:
Five Steps, Every Morning, Forever
The cornerstone of blepharitis management is not medication — it is a daily mechanical routine that removes biofilm, crusts, debris, and Demodex exudate from the lid margin. This must be performed consistently as a lifelong habit, like brushing teeth. It cannot be stopped when symptoms improve without eventual recurrence.
Blepharitis lid hygiene is not a treatment course — it is a permanent daily habit. Symptoms improve when the routine is followed, but if the routine stops, the microbiome imbalance, Demodex population, and meibomian gland blockage return within weeks to months. The analogy is dental plaque: daily brushing prevents accumulation, but stopping brushing allows plaque to build back immediately. Patient adherence is the single most important determinant of long-term blepharitis outcomes.
Medical Treatment:
When Lid Hygiene Alone Is Not Enough
| Treatment | Target | Route | Notes |
|---|---|---|---|
| MOXGUARD (Moxifloxacin 0.5%) | Staphylococcal anterior blepharitis; secondary bacterial conjunctivitis | Topical eye drops, 4× daily | Broad-spectrum fluoroquinolone. Excellent gram-positive coverage (S. aureus, S. epidermidis). Low resistance rates. Use for acute bacterial flares — not as indefinite maintenance. |
| ALPHRIN (Antibiotic + steroid) | Blepharitis with significant inflammatory component; acute flares with conjunctival involvement | Topical, per prescription | Combination antibiotic and anti-inflammatory. Controls both bacterial load and inflammatory response simultaneously. Short course — not for long-term use. IOP monitoring if used beyond 2 weeks. |
| FLUROSCÉNE strips | Assessment — not treatment. Corneal staining to evaluate punctate keratopathy, TBUT | Diagnostic — single use per strip | Essential for assessing associated ocular surface disease (dry eye, SPK from MGD-related tear instability, trichiasis-induced corneal damage). Use at each clinical assessment visit. |
| Topical tea tree oil products | Demodex blepharitis (collarettes confirmed) | Lid margin application (in-clinic 50%; home 1–5%) | Gold standard for Demodex. Terpinen-4-ol is the active moiety. Commercial lid wipes with 1–5% TTO available. 4–50% in-clinic treatment by the doctor. Slow — requires 6–8 weeks minimum. Not available in all Indian pharmacies. |
| Oral doxycycline 50–100 mg/day | Moderate-severe posterior blepharitis/MGD; rosacea-associated; Demodex with inflammatory response | Oral — 4–8 week courses | Reduces MMP-mediated inflammation; modulates meibum composition; has some anti-Demodex effect. Sub-antimicrobial doses (50 mg) have anti-inflammatory effect with minimal antibiotic selection pressure. Widely available in India. |
| Omega-3 fatty acid supplementation | MGD/posterior blepharitis — reduces meibum viscosity | Oral — 2–3 g EPA+DHA daily | Moderate evidence. Reduces inflammatory cytokines in meibum, improves meibum quality and flow. Well-tolerated, widely available in India (fish oil or flaxseed oil capsules). Long-term (3+ months) required for benefit. |
| Cyclosporine 0.05% or 0.09% eye drops | Severe MGD/posterior blepharitis with dry eye disease | Topical — long-term use | Reduces T-cell mediated inflammation on ocular surface. Most effective for the dry eye component of posterior blepharitis. Requires 3+ months before maximal benefit. Available in India (Restasis generics). |
What Untreated Blepharitis
Does Over Time
Blepharitis is not immediately sight-threatening, but chronic untreated blepharitis produces a cascade of complications that progressively worsen ocular health and quality of life:
- Hordeolum (stye) — acute bacterial infection of a lash follicle (external hordeolum) or meibomian gland (internal hordeolum). Painful, swollen lid lump — typically caused by S. aureus. Treatment: warm compresses, topical antibiotic if not resolving. Surgical incision and drainage for persistent cases. Recurrent styes are a red flag for underlying blepharitis — treating the blepharitis prevents recurrence.
- Chalazion — chronic granulomatous reaction to retained meibomian gland secretions. A non-tender, firm, smooth swelling in the lid (distinct from the painful stye). Develops from an obstructed meibomian gland — essentially the chronic form of an internal hordeolum. Management: warm compresses, steroid injection, or surgical incision and curettage for persistent lesions. Recurrent chalazia mandate evaluation for underlying MGD and Demodex.
- Dry eye disease (DED) — the most common complication of posterior blepharitis/MGD. Deficient meibomian lipid layer → accelerated tear evaporation → hyperosmolar tears → corneal surface inflammation → DED symptoms (burning, grittiness, fluctuating vision). In India, environmental factors amplify this: pollution, air conditioning, digital screen use, and low indoor humidity. See our Dry Eye guide for the full DED management framework.
- Trichiasis and madarosis — chronic lid margin inflammation destroys lash follicles, causing lash loss (madarosis) and misdirected lashes (trichiasis). Trichiasis produces corneal abrasion as lashes rub the corneal surface with each blink — this is painful and, untreated, causes corneal scarring and visual impairment. Treatment of trichiasis: epilation, electrolysis, or laser photocoagulation of aberrant follicles.
- Superficial punctate keratopathy (SPK) — micro-erosions on the corneal surface from tear film instability, toxins from Staphylococcal exotoxins, or trichiasis. Visible on FLUROSCÉNE staining as stippled bright spots on the inferior cornea. Not vision-threatening if treated; persistent SPK can progress to corneal neovascularisation and scarring in severe cases.
- Corneal neovascularisation and ulceration — rare complication of severe chronic anterior blepharitis from Staphylococcal marginal keratitis. Peripheral inflammatory infiltrates (Staph marginal keratitis) appear at the 2, 4, 8, and 10 o'clock positions — corresponding to the area of greatest lid-cornea contact during blink. Treat with short-course topical antibiotic + steroid combination.
Five Questions to Ask
Your Ophthalmologist
-
01"I've had recurring styes for two years. Could blepharitis be the underlying cause?"Almost certainly yes. Recurrent styes (hordeola) without a clear single precipitant — infection, trauma — are almost always a sign of underlying chronic blepharitis, most commonly from Staphylococcal colonisation and/or Demodex infestation of the lid margin. Ask your ophthalmologist to examine your lid margin specifically for collarettes (Demodex), follicular changes, and meibomian gland assessment. Treating the underlying blepharitis — not just draining each stye — is what prevents recurrence.
-
02"I use kajal/kohl every day and my eyes are always red and gritty. Could the kajal be causing blepharitis?"Almost certainly contributing, yes. Kajal applied to the inner lid margin (waterline) physically blocks meibomian gland orifices — the openings of the oil glands that keep the eye moist. Studies have found kajal particles inside meibomian glands on imaging. This is a direct mechanical cause of MGD and posterior blepharitis. The advice: if you use eye makeup, apply kajal only to the outer lid skin, never inside the waterline. Remove eye makeup completely every evening before sleep. If you have blepharitis, consider avoiding kajal entirely during treatment and during flares.
-
03"My eyes are dry and gritty — is this blepharitis or dry eye, or both?"Blepharitis and dry eye disease co-exist in the vast majority of posterior blepharitis patients — they are not two separate conditions in this context but two manifestations of the same underlying process (MGD → tear film instability → dry eye). The question "is it blepharitis or dry eye" has a false premise when posterior blepharitis is present. The correct approach is to treat both simultaneously: warm compress + lid massage + antibiotic/anti-inflammatory for the blepharitis component; artificial tears, omega-3 supplements, and possibly cyclosporine for the dry eye component. Fluorescein staining of the corneal surface and TBUT measurement help assess the DED severity.
-
04"My doctor said I have Demodex blepharitis. How is this different from regular blepharitis treatment?"Standard lid hygiene (baby shampoo, warm compresses) does not eliminate Demodex mites — it reduces their food source and improves lid hygiene but doesn't kill the mites or eggs. Specific Demodex treatment requires: tea tree oil–based lid wipes (terpinen-4-ol, the active component) used daily at home, or higher-concentration TTO treatments applied by the clinician at the office. Expect at least 6–8 weeks of consistent treatment before the collarettes (the visible sign of Demodex) begin to resolve. You also need to wash pillowcases, face towels, and any fabric that contacts your eye area regularly in hot water (≥60°C) to prevent reinfestation from the shared-household linen reservoir.
-
05"I have rosacea and my eyes are always irritated. Is this related to my rosacea?"Yes — ocular rosacea affects approximately 58–72% of people with cutaneous rosacea. The eyelid manifestation of rosacea is posterior blepharitis/MGD: inflamed lid margins, telangiectasia of the lid margin blood vessels, chalazia, and severe dry eye. Demodex is considered a co-pathogen in rosacea — higher Demodex densities are found in rosacea patients and Demodex triggers some of the inflammatory responses. Treatment of ocular rosacea requires addressing the underlying systemic condition (oral doxycycline or azithromycin for flares, topical ivermectin or brimonidine for facial rosacea) alongside standard posterior blepharitis lid hygiene. Refer your ophthalmologist to your dermatologist's treatment plan for coordinated management.
Agaaz Ophthalmics:
Three Products for Blepharitis Management
Agaaz Ophthalmics manufactures ophthalmic products directly relevant to the diagnosis and treatment of blepharitis and its complications — manufactured in Narol, Ahmedabad under GMP standards, exported to 15+ countries.
Contact Agaaz: info@agaaz.life · WhatsApp +91 98241 64173
Blepharitis is chronic inflammation of the eyelid margin — the rim where the lashes grow. It affects both eyelids simultaneously and is one of the most common eye conditions worldwide, estimated to affect up to 40% of the Indian population. Causes include: (1) Staphylococcal bacterial overgrowth at the lash follicles (most common cause of anterior blepharitis); (2) Demodex mites — microscopic parasites that inhabit lash follicles and meibomian glands; (3) Meibomian gland dysfunction (MGD) — blockage and inflammation of the oil glands on the inner lid margin, the main cause of posterior blepharitis; (4) Seborrhoeic dermatitis — the same inflammatory skin condition that causes dandruff; (5) Rosacea — a systemic inflammatory skin condition with significant ocular manifestations. Most patients have mixed anterior and posterior blepharitis simultaneously.
The daily lid hygiene routine for blepharitis: Step 1 — Warm compress (5–10 min): Apply a warm, damp cloth to closed eyelids. A reusable microwave-heated eye mask works better than a cloth for consistent temperature. This softens crusts and melts thickened meibomian secretions. Step 2 — Lid massage (optional for MGD): Immediately after warming, gently roll a clean finger along the lid toward the margin to express warmed meibum. Step 3 — Lid scrub: Using a cotton bud moistened with diluted baby shampoo (1–2 drops in 10–20 ml cooled boiled water), gently scrub horizontally along the lash base. Commercial lid wipes with terpinen-4-ol (tea tree oil component) are better for Demodex. Step 4 — Rinse: Rinse with clean water. Step 5 — Drops if prescribed: Apply antibiotic or other prescribed drops after cleaning. This routine must be done daily, indefinitely — stopping causes recurrence within weeks.
No — blepharitis is almost never permanently cured. The underlying factors that cause it (skin type, Demodex ecology, meibomian gland dysfunction, seborrhoeic tendency) are chronic and recurrent. However, blepharitis is highly manageable: consistent daily lid hygiene keeps symptoms controlled, and most patients are symptom-free or minimally symptomatic when compliant with their routine. The analogy: like gingivitis, daily cleaning prevents accumulation; stopping causes return. The goal of treatment is not cure but long-term control. Patients who understand this are more likely to maintain their routine indefinitely and avoid the cycle of treatment → stopping → relapse that is unfortunately common in blepharitis management in India.
Collarettes are cylindrical, waxy, sleeve-like deposits that accumulate at the base of eyelashes — wrapping around individual lashes close to where they emerge from the lid. They are the pathognomonic (diagnostic) sign of Demodex blepharitis — no other type of blepharitis produces true collarettes. They are composed of mite excrement, eggs, keratin debris, and regurgitated material. Visible at the slit lamp, and in severe infestations with a loupe or careful torch examination. Their presence indicates Demodex infestation and requires Demodex-specific treatment (tea tree oil products) in addition to standard lid hygiene. Standard lid scrubs with baby shampoo do not eliminate Demodex or collarettes — targeted treatment is needed. The Titan study found 58% of all eye care clinic patients have collarettes — so if your ophthalmologist hasn't checked, ask them to look specifically.
Kajal applied to the inner waterline is a significant risk factor for posterior blepharitis and MGD in India. The inner lid margin is precisely where meibomian gland orifices open. Kajal particles physically block these orifices, preventing meibum secretion and causing gland obstruction — a direct mechanical cause of MGD. Studies using meibography have found kajal particles within meibomian glands. Kajal use is associated with increased risk of chalazia, MGD, and DED. Safe eye makeup use: apply kajal to the outer lid skin only, never inside the waterline. Always remove eye makeup completely before sleep. If you have blepharitis or MGD, consider avoiding the inner waterline permanently. Many Indian women are not counselled about this — it is one of the most actionable lifestyle changes for reducing recurrent posterior blepharitis in India's female population.
Recurrent styes almost always indicate underlying chronic blepharitis. A single stye is usually a random bacterial infection of one lash follicle or meibomian gland. But recurring styes — two or more per year — signal that the lid margin microenvironment is permanently dysregulated: excess Staphylococcal colonisation, Demodex infestation, or meibomian gland obstruction from MGD creates repeated opportunities for acute bacterial infection. Treating the stye alone (warm compresses, drainage if needed, antibiotic drops) doesn't address the underlying cause. The correct approach: treat the presenting stye AND initiate a long-term blepharitis management programme — daily lid hygiene, appropriate treatment for any Demodex or bacterial overgrowth found on examination. With consistent blepharitis management, recurrent styes typically resolve completely.
Blepharitis itself is not contagious — you cannot "catch" blepharitis from another person through normal contact. The underlying microbial contributors (Staphylococcal bacteria, Demodex mites) are normal skin flora that everyone has; blepharitis develops when their balance is disrupted by individual factors (skin type, age, hygiene, Demodex density). However, there is a nuance for Demodex: while you cannot catch Demodex blepharitis the way you catch a cold, Demodex mites can transfer between people through very close contact (sharing pillowcases, face towels, makeup brushes). If one family member has confirmed Demodex blepharitis, it is reasonable to recommend that other close household members also get examined, avoid sharing pillowcases and face towels, and wash shared linen at ≥60°C regularly during treatment.
Blepharitis — particularly posterior blepharitis/MGD — is the most common cause of evaporative dry eye disease in India. The mechanism: blocked or dysfunctional meibomian glands produce insufficient or abnormal lipid, the tear film lipid layer thins, tears evaporate faster, the tear film becomes hyperosmolar, and this hyperosmolar insult triggers inflammation of the conjunctival and corneal surface. The result is dry eye disease. In India, this is amplified by environmental factors: urban air pollution, dry air from air conditioning, prolonged screen time, and kajal use all worsen tear film stability. Many patients diagnosed with "dry eye" in India have underlying posterior blepharitis as the primary driver — and treating only the dry eye without addressing the blepharitis produces incomplete and temporary relief. Comprehensive management must address both. See our detailed Dry Eye guide.
Diagnosis involves a systematic slit-lamp examination of the lid margin: (1) Anterior lid margin: inspect lash follicles for collarettes (Demodex sign), crusting/scurf, telangiectasia, lid margin thickening or notching, lash loss (madarosis), misdirected lashes (trichiasis). (2) Posterior lid margin: assess meibomian gland orifices — are they open, capped with keratinised plugs, or blocked? Express a few glands gently: what is the quality of meibum? (Clear liquid = normal; cloudy = abnormal; toothpaste-like = severe MGD.) (3) Tear film: measure TBUT with fluorescein (FLUROSCÉNE strip). Normal ≥10 sec; MGD-associated dry eye typically <5 sec. (4) Corneal staining: fluorescein reveals SPK, marginal corneal infiltrates, trichiasis tracks. (5) Conjunctiva: follicular or papillary reaction, injection pattern. This systematic assessment guides treatment — the clinical findings determine whether anterior, posterior, or mixed blepharitis predominates and which treatments to prioritise.
Yes — significantly. Active blepharitis is a risk factor for post-cataract endophthalmitis (sight-threatening eye infection) because the colonised lid margin is the primary source of bacteria that can enter the eye at surgery. S. aureus and S. epidermidis — the dominant organisms in staphylococcal blepharitis — are common causes of post-cataract endophthalmitis. Demodex blepharitis with collarettes is associated with higher bacterial loads. Standard pre-operative blepharitis management is: (1) At least 2–4 weeks of active lid hygiene prior to surgery; (2) Povidone-iodine 5% irrigation of the conjunctival sac at surgery (most important); (3) Intracameral antibiotic prophylaxis (such as MOXGUARD, Agaaz Ophthalmics) at the end of surgery. Some cataract surgeons routinely screen for blepharitis pre-operatively and defer surgery for active severe blepharitis pending treatment. Premium IOL implantation (toric, multifocal, EDOF) is particularly sensitive to pre-existing blepharitis-associated dry eye — the biometry and patient satisfaction are significantly worse if dry eye and tear film instability are not treated first.
Peer-Reviewed References
Blepharitis management begins
at the slit lamp.
MOXGUARD (moxifloxacin), ALPHRIN (antibiotic + steroid), and FLUROSCÉNE (diagnostic staining) — Agaaz's ophthalmic range for blepharitis and ocular surface disease. GMP certified. Made in Ahmedabad.
Your Eyelids Have Microbiomes.
When They Go Wrong,
You Feel It Every Morning.
Blepharitis affects up to 40% of the Indian population — and most people who have it have never heard the word. Crusty lashes, burning eyes, styes that keep returning: this is the eyelid's chronic inflammatory disease. It doesn't cure, but it controls.
population affected
have Demodex collarettes
untrained in Demodex
in adults over 70
Blepharitis is chronic inflammation of the eyelid margin — among the most common eye conditions in India, estimated to affect up to 40% of the population. Symptoms: morning crusting of lashes, itching, burning, redness, sticky eyelids, and recurring styes or chalazia. Two main types: Anterior blepharitis (outer lid margin, lash follicles — caused by Staphylococcal bacteria and Demodex mites) and Posterior blepharitis (inner lid — caused by meibomian gland dysfunction, MGD). Demodex mites are microscopic parasites in lash follicles and meibomian glands — the Titan study found 58% of eye clinic patients have collarettes, the pathognomonic sign of Demodex blepharitis. Treatment: Daily lid hygiene (warm compress 5–10 min → lid scrub with baby shampoo or commercial wipes → rinse), antibiotic drops or ointment for bacterial flares (MOXGUARD, Agaaz Ophthalmics), warm compress + massage for MGD. Blepharitis is rarely cured but is effectively controlled with consistent daily routine. India-specific note: Demodex blepharitis is highly underdiagnosed in India — 70% of practitioners have no formal training in its detection.
The Eyelid Margin:
Six Millimetres of Extraordinary Complexity
The eyelid margin — the rim you see when you look closely at your eye — is only about 6mm wide, but contains an extraordinary microenvironment that supports both vision and eye protection. Understanding why blepharitis is so common and so persistent requires understanding what lives and functions at this margin.
The upper and lower lid margins are divided anatomically by the grey line (the mucocutaneous junction) into an anterior lamella and a posterior lamella. The anterior lamella contains the skin, the orbicularis muscle, and most critically, the lash follicles — each one capable of harbouring Demodex folliculorum and bacterial colonies. The posterior lamella, separated by the grey line, contains the tarsal plate and within it, a row of 25–40 meibomian glands per eyelid — modified sebaceous glands that secrete the oily outer layer of the tear film.
The meibomian glands open at the posterior lid margin and constantly release a lipid-rich secretion (meibum) onto the eye's surface. This lipid layer prevents tear evaporation and keeps the ocular surface moist. When the meibomian glands become blocked or inflamed — as in posterior blepharitis and MGD — this lipid secretion becomes abnormal, tear film instability results, and the chronic irritation cycle of posterior blepharitis begins.
The lid margin also hosts a resident microbiome: Staphylococcus epidermidis, Corynebacterium species, and Demodex mites in normal flora. When the balance of this microbiome shifts — overgrowth of S. aureus, explosive Demodex proliferation, or dysregulation from seborrhoeic dermatitis — blepharitis develops and persists.
EYELID MARGIN CROSS-SECTION — ANTERIOR vs POSTERIOR ANATOMY
The grey line divides the lid margin. Anterior: lash follicles with Demodex and bacteria. Posterior: meibomian glands producing the tear film's oil layer — blocked in posterior blepharitis. Collarettes at the lash base are the pathognomonic sign of Demodex infestation.
Anterior or Posterior?
Two Different Diseases, Same Eyelid
- Staphylococcal overgrowth (S. epidermidis, S. aureus)
- Seborrhoeic dermatitis (dandruff of the lid margin)
- Demodex folliculorum (mite colonisation of lash follicles)
- Mixed — staphylococcal + seborrhoeic most common combination
- Collarettes — waxy cylindrical deposits at lash base
- Crusting / scurf of lashes (worse on waking)
- Lash loss (madarosis) or misdirected lashes (trichiasis)
- Follicular conjunctivitis, mild keratopathy at 2 & 10 o'clock
- Lid scrubs daily (baby shampoo / commercial wipes)
- Antibiotic ointment (chloramphenicol, fusidic acid) — lid margin application
- Tea tree oil products (for confirmed Demodex)
- Topical antibiotic drops for secondary conjunctivitis
- Oral doxycycline (low-dose) for severe/persistent cases
- Staphylococcal: good control with daily hygiene
- Demodex: requires targeted treatment, slow response (6–8 wks)
- Seborrhoeic: control of scalp dandruff also helps
- Meibomian gland dysfunction (MGD) — primary cause
- Demodex brevis (inhabits meibomian glands, causes atrophy)
- Rosacea — a major associated systemic condition
- Seborrhoeic dermatitis — often co-exists
- Atopic dermatitis, psoriasis in some patients
- Blocked meibomian gland orifices (plugged, thickened meibum)
- Lid margin telangiectasia (fine blood vessels at posterior margin)
- Frothy or foamy tear meniscus
- Irregular posterior lid margin, notching
- Decreased tear break-up time (TBUT), dry eye symptoms
- Warm compress 5–10 min (melts thickened meibum)
- Lid massage (expressed blocked glands after warming)
- Omega-3 supplementation (reduces meibum viscosity)
- Topical cyclosporine or lifitegrast for DED component
- Oral doxycycline 50–100 mg/day for 4–8 weeks
- In-office procedures: meibomian gland expression, Lipiflow
- Lid scrubs help less — warm compress + massage are primary
- Often requires treating the associated DED simultaneously
- Fluorescein staining helpful to assess ocular surface
The Demodex Mite:
What's Living at Your Lash Base
Demodex folliculorum and Demodex brevis are microscopic obligate ectoparasitic mites — members of the Arachnida class — that are the most common human ectoparasites. They live exclusively on mammalian skin, primarily the face, and have no free-living stage. D. folliculorum (0.3–0.4 mm) clusters in groups of 3–8 within the eyelash hair follicle; D. brevis (0.15–0.2 mm) inhabits the meibomian glands and sebaceous glands deeper in the lid.
In normal numbers, Demodex mites are harmless commensal organisms. Pathology occurs when mite density exceeds approximately 1 mite per eyelash — the threshold associated with clinical blepharitis. Several factors drive overpopulation:
- Age — the single strongest determinant. Demodex prevalence rises from ~8% in those under 25 years to ~77% in those over 70 years. By middle age (40–60 years), over 50% of the population has significant Demodex colonisation.
- Rosacea — patients with rosacea have dramatically elevated Demodex densities on the face and lids. Demodex is now considered a contributor to rosacea pathology, not just a bystander.
- Immunosuppression — HIV, immunosuppressive medications, and transplant patients have higher Demodex loads.
- Poor lid hygiene — accumulated sebum and debris provide an ideal growth substrate for Demodex reproduction.
- Seborrhoeic skin type — oilier skin supports larger Demodex populations.
The pathognomonic sign of Demodex blepharitis is collarettes — cylindrical, translucent-to-opaque, waxy, sleeve-like deposits that wrap around the base of eyelashes. They are composed of keratin, mite excrement, eggs, and regurgitated undigested material. Collarettes are visible at the slit lamp and, in severe cases, can be seen with a torch or loupe. Their presence confirms Demodex infestation — no other type of blepharitis produces true collarettes.
"The Titan study found that 58% of US eye care clinic patients — across all presenting complaints, not only blepharitis — exhibited collarettes, confirming that Demodex blepharitis is not a rare or specialist condition but a routine finding that demands routine screening at every slit-lamp examination."
— Adapted from Trattler W, et al. "The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes." Clin Ophthalmol. 2022;16:1153–1164.The treatment for Demodex blepharitis specifically requires agents that target the mite — standard lid hygiene is insufficient. Established approaches:
- Tea tree oil (TTO) — the historically recommended treatment. 4–50% concentrations applied by the clinician to lids; 1–2% dilutions in commercial lid wipes for home use. Terpinen-4-ol (the active component) is the most effective fraction against Demodex. Complete collarette resolution typically takes 6–8 weeks of consistent use.
- Lotilaner ophthalmic solution 0.25% (Xdemvy — Tarsus Pharmaceuticals, approved FDA 2023) — a selective antiparasitic eye drop used twice daily for 6 weeks; the first FDA-approved prescription treatment specifically for Demodex blepharitis. Not yet widely available in India as of mid-2026.
- Oral ivermectin — used off-label; modest evidence for Demodex reduction but systemic side effects limit routine use.
- Hypochlorous acid eyelid cleansers — anti-biofilm and mild anti-Demodex effect; useful as maintenance after acute treatment.
Meibomian Gland Dysfunction:
The Dominant Driver of Posterior Blepharitis
Meibomian gland dysfunction (MGD) is defined as a chronic, diffuse abnormality of the meibomian glands, commonly characterised by terminal duct obstruction and/or qualitative/quantitative changes in glandular secretion — and is the most common cause of evaporative dry eye and posterior blepharitis worldwide.
The meibomian glands (25–40 per lid) are modified holocrine sebaceous glands whose acinar cells synthesise meibum — a complex lipid mixture that forms the outermost layer of the tear film. Meibum prevents tear evaporation, contributes to tear film spreading, and protects the ocular surface. When meibomian glands become obstructed — from stagnant, keratinised ductal epithelium, thickened meibum, or Demodex brevis disruption — meibum cannot flow freely, tear film lipid layer becomes deficient, and the vicious cycle of evaporative dry eye, inflammation, and further gland damage begins.
The link between Demodex and MGD is now well-established. A 2025 study (Yeu and Koetting, published in Journal of Cataract and Refractive Surgery) found that among MGD patients, 45% had Demodex blepharitis — and among those with moderate-to-severe Demodex (≥10 collarettes), 96–99% had concurrent MGD. This bidirectional relationship means that in India, where Demodex is significantly underdiagnosed, many patients treated for "dry eye" or "MGD" are not receiving Demodex-targeted treatment — and thus not addressing a primary driving factor of their condition.
also have Demodex
patients have MGD
globally (age-dependent)
key diagnostic test
India: 40% Prevalence,
Massively Undertreated Demodex
A 2023 survey-based study on Demodex blepharitis knowledge among Indian eye care practitioners (published in Dove Press / Clinical Optometry) produced sobering findings about the state of blepharitis management in India:
- Estimated blepharitis prevalence in the general Indian population: ~40% (as reported by surveyed practitioners).
- 70% of Indian optometrists had received no formal training in Demodex detection or treatment.
- Only 30% of practitioners actively intervened to diagnose and manage Demodex blepharitis — despite 66% agreeing it was a significant cause of ocular discomfort.
- Primary management focus: improving patient comfort (40%), improving meibomian gland secretion (20.8%), eliminating mites (20.8%).
Several India-specific factors compound the blepharitis problem:
- High seborrhoeic dermatitis prevalence — seborrhoeic skin is common in India's climate, and seborrhoeic blepharitis is its ocular manifestation. Both conditions share the same Malassezia yeast contribution and respond to similar treatment (anti-dandruff shampoo for scalp, lid hygiene for lid margins).
- Smoke and pollution exposure — urban air pollution and indoor cooking smoke (biomass fuel, especially in rural areas) are significant environmental irritants that destabilise the tear film and trigger MGD exacerbations.
- Contact lens wear without lid hygiene — increasingly common among India's young urban population; contact lens wear significantly increases Demodex load and Staphylococcal lid margin colonisation.
- Extensive eye makeup use — kajal/kohl application directly to the inner lid margin is extremely common and directly obstructs meibomian gland orifices, contributing to MGD in India's female population. Kajal particles have been found in meibomian glands on meibography.
INDIA-SPECIFIC BLEPHARITIS RISK FACTORS — PREVALENCE MAPPING
Kajal (kohl, surma) applied to the inner lid margin — the waterline — is a widespread practice across all age groups in India, including in children. The inner lid margin is precisely where meibomian gland orifices open. Kajal particles physically obstruct these orifices. Studies have documented kajal particles within meibomian glands on meibography, and kajal use is an independent risk factor for MGD and posterior blepharitis. Patients with recurrent MGD or posterior blepharitis should be specifically counselled to apply kajal only to the outer lid skin, never inside the waterline.
The Lid Hygiene Routine:
Five Steps, Every Morning, Forever
The cornerstone of blepharitis management is not medication — it is a daily mechanical routine that removes biofilm, crusts, debris, and Demodex exudate from the lid margin. This must be performed consistently as a lifelong habit, like brushing teeth. It cannot be stopped when symptoms improve without eventual recurrence.
Blepharitis lid hygiene is not a treatment course — it is a permanent daily habit. Symptoms improve when the routine is followed, but if the routine stops, the microbiome imbalance, Demodex population, and meibomian gland blockage return within weeks to months. The analogy is dental plaque: daily brushing prevents accumulation, but stopping brushing allows plaque to build back immediately. Patient adherence is the single most important determinant of long-term blepharitis outcomes.
Medical Treatment:
When Lid Hygiene Alone Is Not Enough
| Treatment | Target | Route | Notes |
|---|---|---|---|
| MOXGUARD (Moxifloxacin 0.5%) | Staphylococcal anterior blepharitis; secondary bacterial conjunctivitis | Topical eye drops, 4× daily | Broad-spectrum fluoroquinolone. Excellent gram-positive coverage (S. aureus, S. epidermidis). Low resistance rates. Use for acute bacterial flares — not as indefinite maintenance. |
| ALPHRIN (Antibiotic + steroid) | Blepharitis with significant inflammatory component; acute flares with conjunctival involvement | Topical, per prescription | Combination antibiotic and anti-inflammatory. Controls both bacterial load and inflammatory response simultaneously. Short course — not for long-term use. IOP monitoring if used beyond 2 weeks. |
| FLUROSCÉNE strips | Assessment — not treatment. Corneal staining to evaluate punctate keratopathy, TBUT | Diagnostic — single use per strip | Essential for assessing associated ocular surface disease (dry eye, SPK from MGD-related tear instability, trichiasis-induced corneal damage). Use at each clinical assessment visit. |
| Topical tea tree oil products | Demodex blepharitis (collarettes confirmed) | Lid margin application (in-clinic 50%; home 1–5%) | Gold standard for Demodex. Terpinen-4-ol is the active moiety. Commercial lid wipes with 1–5% TTO available. 4–50% in-clinic treatment by the doctor. Slow — requires 6–8 weeks minimum. Not available in all Indian pharmacies. |
| Oral doxycycline 50–100 mg/day | Moderate-severe posterior blepharitis/MGD; rosacea-associated; Demodex with inflammatory response | Oral — 4–8 week courses | Reduces MMP-mediated inflammation; modulates meibum composition; has some anti-Demodex effect. Sub-antimicrobial doses (50 mg) have anti-inflammatory effect with minimal antibiotic selection pressure. Widely available in India. |
| Omega-3 fatty acid supplementation | MGD/posterior blepharitis — reduces meibum viscosity | Oral — 2–3 g EPA+DHA daily | Moderate evidence. Reduces inflammatory cytokines in meibum, improves meibum quality and flow. Well-tolerated, widely available in India (fish oil or flaxseed oil capsules). Long-term (3+ months) required for benefit. |
| Cyclosporine 0.05% or 0.09% eye drops | Severe MGD/posterior blepharitis with dry eye disease | Topical — long-term use | Reduces T-cell mediated inflammation on ocular surface. Most effective for the dry eye component of posterior blepharitis. Requires 3+ months before maximal benefit. Available in India (Restasis generics). |
What Untreated Blepharitis
Does Over Time
Blepharitis is not immediately sight-threatening, but chronic untreated blepharitis produces a cascade of complications that progressively worsen ocular health and quality of life:
- Hordeolum (stye) — acute bacterial infection of a lash follicle (external hordeolum) or meibomian gland (internal hordeolum). Painful, swollen lid lump — typically caused by S. aureus. Treatment: warm compresses, topical antibiotic if not resolving. Surgical incision and drainage for persistent cases. Recurrent styes are a red flag for underlying blepharitis — treating the blepharitis prevents recurrence.
- Chalazion — chronic granulomatous reaction to retained meibomian gland secretions. A non-tender, firm, smooth swelling in the lid (distinct from the painful stye). Develops from an obstructed meibomian gland — essentially the chronic form of an internal hordeolum. Management: warm compresses, steroid injection, or surgical incision and curettage for persistent lesions. Recurrent chalazia mandate evaluation for underlying MGD and Demodex.
- Dry eye disease (DED) — the most common complication of posterior blepharitis/MGD. Deficient meibomian lipid layer → accelerated tear evaporation → hyperosmolar tears → corneal surface inflammation → DED symptoms (burning, grittiness, fluctuating vision). In India, environmental factors amplify this: pollution, air conditioning, digital screen use, and low indoor humidity. See our Dry Eye guide for the full DED management framework.
- Trichiasis and madarosis — chronic lid margin inflammation destroys lash follicles, causing lash loss (madarosis) and misdirected lashes (trichiasis). Trichiasis produces corneal abrasion as lashes rub the corneal surface with each blink — this is painful and, untreated, causes corneal scarring and visual impairment. Treatment of trichiasis: epilation, electrolysis, or laser photocoagulation of aberrant follicles.
- Superficial punctate keratopathy (SPK) — micro-erosions on the corneal surface from tear film instability, toxins from Staphylococcal exotoxins, or trichiasis. Visible on FLUROSCÉNE staining as stippled bright spots on the inferior cornea. Not vision-threatening if treated; persistent SPK can progress to corneal neovascularisation and scarring in severe cases.
- Corneal neovascularisation and ulceration — rare complication of severe chronic anterior blepharitis from Staphylococcal marginal keratitis. Peripheral inflammatory infiltrates (Staph marginal keratitis) appear at the 2, 4, 8, and 10 o'clock positions — corresponding to the area of greatest lid-cornea contact during blink. Treat with short-course topical antibiotic + steroid combination.
Five Questions to Ask
Your Ophthalmologist
-
01"I've had recurring styes for two years. Could blepharitis be the underlying cause?"Almost certainly yes. Recurrent styes (hordeola) without a clear single precipitant — infection, trauma — are almost always a sign of underlying chronic blepharitis, most commonly from Staphylococcal colonisation and/or Demodex infestation of the lid margin. Ask your ophthalmologist to examine your lid margin specifically for collarettes (Demodex), follicular changes, and meibomian gland assessment. Treating the underlying blepharitis — not just draining each stye — is what prevents recurrence.
-
02"I use kajal/kohl every day and my eyes are always red and gritty. Could the kajal be causing blepharitis?"Almost certainly contributing, yes. Kajal applied to the inner lid margin (waterline) physically blocks meibomian gland orifices — the openings of the oil glands that keep the eye moist. Studies have found kajal particles inside meibomian glands on imaging. This is a direct mechanical cause of MGD and posterior blepharitis. The advice: if you use eye makeup, apply kajal only to the outer lid skin, never inside the waterline. Remove eye makeup completely every evening before sleep. If you have blepharitis, consider avoiding kajal entirely during treatment and during flares.
-
03"My eyes are dry and gritty — is this blepharitis or dry eye, or both?"Blepharitis and dry eye disease co-exist in the vast majority of posterior blepharitis patients — they are not two separate conditions in this context but two manifestations of the same underlying process (MGD → tear film instability → dry eye). The question "is it blepharitis or dry eye" has a false premise when posterior blepharitis is present. The correct approach is to treat both simultaneously: warm compress + lid massage + antibiotic/anti-inflammatory for the blepharitis component; artificial tears, omega-3 supplements, and possibly cyclosporine for the dry eye component. Fluorescein staining of the corneal surface and TBUT measurement help assess the DED severity.
-
04"My doctor said I have Demodex blepharitis. How is this different from regular blepharitis treatment?"Standard lid hygiene (baby shampoo, warm compresses) does not eliminate Demodex mites — it reduces their food source and improves lid hygiene but doesn't kill the mites or eggs. Specific Demodex treatment requires: tea tree oil–based lid wipes (terpinen-4-ol, the active component) used daily at home, or higher-concentration TTO treatments applied by the clinician at the office. Expect at least 6–8 weeks of consistent treatment before the collarettes (the visible sign of Demodex) begin to resolve. You also need to wash pillowcases, face towels, and any fabric that contacts your eye area regularly in hot water (≥60°C) to prevent reinfestation from the shared-household linen reservoir.
-
05"I have rosacea and my eyes are always irritated. Is this related to my rosacea?"Yes — ocular rosacea affects approximately 58–72% of people with cutaneous rosacea. The eyelid manifestation of rosacea is posterior blepharitis/MGD: inflamed lid margins, telangiectasia of the lid margin blood vessels, chalazia, and severe dry eye. Demodex is considered a co-pathogen in rosacea — higher Demodex densities are found in rosacea patients and Demodex triggers some of the inflammatory responses. Treatment of ocular rosacea requires addressing the underlying systemic condition (oral doxycycline or azithromycin for flares, topical ivermectin or brimonidine for facial rosacea) alongside standard posterior blepharitis lid hygiene. Refer your ophthalmologist to your dermatologist's treatment plan for coordinated management.
Agaaz Ophthalmics:
Three Products for Blepharitis Management
Agaaz Ophthalmics manufactures ophthalmic products directly relevant to the diagnosis and treatment of blepharitis and its complications — manufactured in Narol, Ahmedabad under GMP standards, exported to 15+ countries.
Contact Agaaz: info@agaaz.life · WhatsApp +91 98241 64173
Blepharitis is chronic inflammation of the eyelid margin — the rim where the lashes grow. It affects both eyelids simultaneously and is one of the most common eye conditions worldwide, estimated to affect up to 40% of the Indian population. Causes include: (1) Staphylococcal bacterial overgrowth at the lash follicles (most common cause of anterior blepharitis); (2) Demodex mites — microscopic parasites that inhabit lash follicles and meibomian glands; (3) Meibomian gland dysfunction (MGD) — blockage and inflammation of the oil glands on the inner lid margin, the main cause of posterior blepharitis; (4) Seborrhoeic dermatitis — the same inflammatory skin condition that causes dandruff; (5) Rosacea — a systemic inflammatory skin condition with significant ocular manifestations. Most patients have mixed anterior and posterior blepharitis simultaneously.
The daily lid hygiene routine for blepharitis: Step 1 — Warm compress (5–10 min): Apply a warm, damp cloth to closed eyelids. A reusable microwave-heated eye mask works better than a cloth for consistent temperature. This softens crusts and melts thickened meibomian secretions. Step 2 — Lid massage (optional for MGD): Immediately after warming, gently roll a clean finger along the lid toward the margin to express warmed meibum. Step 3 — Lid scrub: Using a cotton bud moistened with diluted baby shampoo (1–2 drops in 10–20 ml cooled boiled water), gently scrub horizontally along the lash base. Commercial lid wipes with terpinen-4-ol (tea tree oil component) are better for Demodex. Step 4 — Rinse: Rinse with clean water. Step 5 — Drops if prescribed: Apply antibiotic or other prescribed drops after cleaning. This routine must be done daily, indefinitely — stopping causes recurrence within weeks.
No — blepharitis is almost never permanently cured. The underlying factors that cause it (skin type, Demodex ecology, meibomian gland dysfunction, seborrhoeic tendency) are chronic and recurrent. However, blepharitis is highly manageable: consistent daily lid hygiene keeps symptoms controlled, and most patients are symptom-free or minimally symptomatic when compliant with their routine. The analogy: like gingivitis, daily cleaning prevents accumulation; stopping causes return. The goal of treatment is not cure but long-term control. Patients who understand this are more likely to maintain their routine indefinitely and avoid the cycle of treatment → stopping → relapse that is unfortunately common in blepharitis management in India.
Collarettes are cylindrical, waxy, sleeve-like deposits that accumulate at the base of eyelashes — wrapping around individual lashes close to where they emerge from the lid. They are the pathognomonic (diagnostic) sign of Demodex blepharitis — no other type of blepharitis produces true collarettes. They are composed of mite excrement, eggs, keratin debris, and regurgitated material. Visible at the slit lamp, and in severe infestations with a loupe or careful torch examination. Their presence indicates Demodex infestation and requires Demodex-specific treatment (tea tree oil products) in addition to standard lid hygiene. Standard lid scrubs with baby shampoo do not eliminate Demodex or collarettes — targeted treatment is needed. The Titan study found 58% of all eye care clinic patients have collarettes — so if your ophthalmologist hasn't checked, ask them to look specifically.
Kajal applied to the inner waterline is a significant risk factor for posterior blepharitis and MGD in India. The inner lid margin is precisely where meibomian gland orifices open. Kajal particles physically block these orifices, preventing meibum secretion and causing gland obstruction — a direct mechanical cause of MGD. Studies using meibography have found kajal particles within meibomian glands. Kajal use is associated with increased risk of chalazia, MGD, and DED. Safe eye makeup use: apply kajal to the outer lid skin only, never inside the waterline. Always remove eye makeup completely before sleep. If you have blepharitis or MGD, consider avoiding the inner waterline permanently. Many Indian women are not counselled about this — it is one of the most actionable lifestyle changes for reducing recurrent posterior blepharitis in India's female population.
Recurrent styes almost always indicate underlying chronic blepharitis. A single stye is usually a random bacterial infection of one lash follicle or meibomian gland. But recurring styes — two or more per year — signal that the lid margin microenvironment is permanently dysregulated: excess Staphylococcal colonisation, Demodex infestation, or meibomian gland obstruction from MGD creates repeated opportunities for acute bacterial infection. Treating the stye alone (warm compresses, drainage if needed, antibiotic drops) doesn't address the underlying cause. The correct approach: treat the presenting stye AND initiate a long-term blepharitis management programme — daily lid hygiene, appropriate treatment for any Demodex or bacterial overgrowth found on examination. With consistent blepharitis management, recurrent styes typically resolve completely.
Blepharitis itself is not contagious — you cannot "catch" blepharitis from another person through normal contact. The underlying microbial contributors (Staphylococcal bacteria, Demodex mites) are normal skin flora that everyone has; blepharitis develops when their balance is disrupted by individual factors (skin type, age, hygiene, Demodex density). However, there is a nuance for Demodex: while you cannot catch Demodex blepharitis the way you catch a cold, Demodex mites can transfer between people through very close contact (sharing pillowcases, face towels, makeup brushes). If one family member has confirmed Demodex blepharitis, it is reasonable to recommend that other close household members also get examined, avoid sharing pillowcases and face towels, and wash shared linen at ≥60°C regularly during treatment.
Blepharitis — particularly posterior blepharitis/MGD — is the most common cause of evaporative dry eye disease in India. The mechanism: blocked or dysfunctional meibomian glands produce insufficient or abnormal lipid, the tear film lipid layer thins, tears evaporate faster, the tear film becomes hyperosmolar, and this hyperosmolar insult triggers inflammation of the conjunctival and corneal surface. The result is dry eye disease. In India, this is amplified by environmental factors: urban air pollution, dry air from air conditioning, prolonged screen time, and kajal use all worsen tear film stability. Many patients diagnosed with "dry eye" in India have underlying posterior blepharitis as the primary driver — and treating only the dry eye without addressing the blepharitis produces incomplete and temporary relief. Comprehensive management must address both. See our detailed Dry Eye guide.
Diagnosis involves a systematic slit-lamp examination of the lid margin: (1) Anterior lid margin: inspect lash follicles for collarettes (Demodex sign), crusting/scurf, telangiectasia, lid margin thickening or notching, lash loss (madarosis), misdirected lashes (trichiasis). (2) Posterior lid margin: assess meibomian gland orifices — are they open, capped with keratinised plugs, or blocked? Express a few glands gently: what is the quality of meibum? (Clear liquid = normal; cloudy = abnormal; toothpaste-like = severe MGD.) (3) Tear film: measure TBUT with fluorescein (FLUROSCÉNE strip). Normal ≥10 sec; MGD-associated dry eye typically <5 sec. (4) Corneal staining: fluorescein reveals SPK, marginal corneal infiltrates, trichiasis tracks. (5) Conjunctiva: follicular or papillary reaction, injection pattern. This systematic assessment guides treatment — the clinical findings determine whether anterior, posterior, or mixed blepharitis predominates and which treatments to prioritise.
Yes — significantly. Active blepharitis is a risk factor for post-cataract endophthalmitis (sight-threatening eye infection) because the colonised lid margin is the primary source of bacteria that can enter the eye at surgery. S. aureus and S. epidermidis — the dominant organisms in staphylococcal blepharitis — are common causes of post-cataract endophthalmitis. Demodex blepharitis with collarettes is associated with higher bacterial loads. Standard pre-operative blepharitis management is: (1) At least 2–4 weeks of active lid hygiene prior to surgery; (2) Povidone-iodine 5% irrigation of the conjunctival sac at surgery (most important); (3) Intracameral antibiotic prophylaxis (such as MOXGUARD, Agaaz Ophthalmics) at the end of surgery. Some cataract surgeons routinely screen for blepharitis pre-operatively and defer surgery for active severe blepharitis pending treatment. Premium IOL implantation (toric, multifocal, EDOF) is particularly sensitive to pre-existing blepharitis-associated dry eye — the biometry and patient satisfaction are significantly worse if dry eye and tear film instability are not treated first.
Peer-Reviewed References
Blepharitis management begins
at the slit lamp.
MOXGUARD (moxifloxacin), ALPHRIN (antibiotic + steroid), and FLUROSCÉNE (diagnostic staining) — Agaaz's ophthalmic range for blepharitis and ocular surface disease. GMP certified. Made in Ahmedabad.
Start writing here...
Blepharitis: Eyelid Inflammation & Lid Hygiene India 2026